New Zealand - English - Medsafe (Medicines Safety Authority)

astrazeneca limited - acalabrutinib 100mg - capsule - 100 mg - active: acalabrutinib 100mg excipient: black ink (calquence) gelatin indigo carmine iron oxide yellow magnesium stearate silicified microcrystalline cellulose sodium starch glycolate starch titanium dioxide - calquence is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. calquence is indicated for the treatment of patients with chronic lymphocytic leukaemia (cll)/small lymphocytic lymphoma (sll).

United States - English - NLM (National Library of Medicine)

stat rx usa llc - quinine sulfate (unii: kf7z0e0q2b) (quinine - unii:a7v27phc7a) - quinine sulfate 324 mg - qualaquin (quinine sulfate) is an antimalarial drug indicated only for treatment of uncomplicated plasmodium falciparum malaria. quinine sulfate has been shown to be effective in geographical regions where resistance to chloroquine has been documented [see clinical studies (14) ]. qualaquin oral capsules are not approved for: - treatment of severe or complicated p. falciparum malaria. - prevention of malaria. - treatment or prevention of nocturnal leg cramps [see warnings and precautions (5.1) ]. qualaquin is contraindicated in patients with the following: - prolonged qt interval. one case of a fatal ventricular arrhythmia was reported in an elderly patient with a prolonged qt interval at baseline, who received quinine sulfate intravenously for p. falciparum malaria [see warnings and precautions (5.3) ]. - glucose-6-phosphate dehydrogenase (g6pd) deficiency. - hemolysis can occur in patients with g6pd deficiency receiving quinine. - known hypersensitivity reactions to quinine. these include, but are not li

Israel - English - Ministry of Health

pfizer pharmaceuticals israel ltd - crisaborole - ointment - crisaborole 2 %w/w - staquis is indicated for topical treatment of mild to moderate atopic dermatitis in adult and pediatric patients 3 months of age and older

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

aqui-s new zealand limited - isoeugenol - topical solution/suspension - isoeugenol oil-plant extract active 540.0 g/l - anaesthetics/analgesics - salmonids - anaesthetic - local/general | general anaesthetic | immobiliser | local anaesthetic | premedication | sedative | tranquilliser | travel sickness

New Zealand - English - Medsafe (Medicines Safety Authority)

astrazeneca limited - primaquine phosphate 7.5mg - tablet - 7.5 mg - active: primaquine phosphate 7.5mg

Canada - English - Health Canada

dominion veterinary laboratories ltd. - sulfaquinoxaline (sulfaquinoxaline sodium) - solution - 19.2% - sulfaquinoxaline (sulfaquinoxaline sodium) 19.2% - poultry; poultry

Canada - English - Health Canada

professional veterinary laboratories - sulfaquinoxaline - solution - 19.2% - sulfaquinoxaline 19.2% - poultry; poultry; poultry; poultry

United States - English - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - levofloxacin (unii: 6gnt3y5lmf) (levofloxacin anhydrous - unii:rix4e89y14) - levofloxacin anhydrous 500 mg - levaquin ® is indicated in adult patients for the treatment of nosocomial pneumonia due to methicillin-susceptible staphylococcus aureus , pseudomonas aeruginosa , serratia marcescens , escherichia coli , klebsiella pneumoniae , haemophilus influenzae , or streptococcus pneumoniae . adjunctive therapy should be used as clinically indicated. where pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended [see clinical studies (14.1)] . levaquin ® is indicated in adult patients for the treatment of community-acquired pneumonia due to methicillin-susceptible staphylococcus aureus , streptococcus pneumoniae (including multi-drug-resistant streptococcus pneumoniae [mdrsp]), haemophilus influenzae , haemophilus parainfluenzae , klebsiella pneumoniae , moraxella catarrhalis , chlamydophila pneumoniae , legionella pneumophila , or mycoplasma pneumoniae [see dosage and administration (2.1) and clinical studies (14.2)] . mdrsp isolates ar

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - levofloxacin (unii: 6gnt3y5lmf) (levofloxacin - unii:6gnt3y5lmf) - levofloxacin 250 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of levaquin® and other antibacterial drugs, levaquin® should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. levaquin® tablets/injection and oral solution are indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible strains of the designated microorganisms in the conditions listed in this section. levaquin® injection is indicated when intravenous administration offers a route of administration advantageous to the patient (e.g., patient cannot tolerate an oral dosage form). culture and susceptibility testing appropriate culture and

United States - English - NLM (National Library of Medicine)

rebel distributors corp - levofloxacin (unii: 6gnt3y5lmf) (levofloxacin - unii:6gnt3y5lmf) - levofloxacin 500 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of levaquin® and other antibacterial drugs, levaquin® should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. levaquin® tablets/injection and oral solution are indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible strains of the designated microorganisms in the conditions listed in this section. levaquin® injection is indicated when intravenous administration offers a route of administration advantageous to the patient (e.g., patient cannot tolerate an oral dosage form). culture and susceptibility testing appropriate culture and